Amyloid-beta binding proteins
AssigneesAbbott Laboratories, Abbott GmbH & Co. KG
InventorsStefan Barghorn, Heinz Hillen, Andreas Striebinger, Simone Giaisi, Ulrich Ebert, Lorenzo Benatuil
Life of this patent
Estimating the term…
Abstract
The present invention relates to amyloid-beta (Aβ) binding proteins. Antibodies of the invention have high affinity to Aβ(20-42) globulomer or any Aβ form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
Claims17
A binding protein comprising:
- a first amino acid sequence which is at least 90% identical to SEQ ID NO:2 or SEQ ID NO:3;
- and a second amino acid sequence which is at least 90% identical to SEQ ID NO:1.
The binding protein of any one of claims 1 to 6 further comprising an immunoglobulin light chain constant region having an amino acid sequence selected from the group consisting of SEQ ID NO:27 and SEQ ID NO:28.
The binding protein according to any one of claims 1 to 7, wherein said binding protein further comprises an agent selected from the group consisting of:
- an immunoadhesion molecule;
- an imaging agent, and a therapeutic agent.
A pharmaceutical composition comprising the binding protein of any one of claim 1 to 8 or 14, and a pharmaceutically acceptable carrier.
A method for treating a subject for a disease or a disorder selected from the group consisting of Alpha1-antitrypsin-deficiency, C1-inhibitor deficiency angioedema, Antithrombin deficiency thromboembolic disease, Kuru, Creutzfeld-Jacob disease/scrapie, Bovine spongiform encephalopathy, Gerstmann-Straussler-Scheinker disease, Fatal familial insomnia, Huntington's disease, Spinocerebellar ataxia, Machado-Joseph atrophy, Dentato-rubro-pallidoluysian atrophy, Frontotemporal dementia, Sickle cell anemia, Unstable hemoglobin inclusion-body hemolysis, Drug-induced inclusion body hemolysis, Parkinson's disease, Systemic AL amyloidosis, Nodular AL amyloidosis, Systemic AA amyloidosis, Prostatic amyloidosis, Hemodialysis amyloidosis, Hereditary (Icelandic) cerebral angiopathy, Huntington's disease, Familial visceral amyloidosis, Familial visceral polyneuropathy, Familial visceral amyloidosis, Senile systemic amyloidosis, Familial amyloid neurophathy, Familial cardiac amyloidosis, Alzheimer's disease, Down syndrome, Medullary carcinoma thyroid and Type 2 diabetes mellitus (T2DM) by administering to the subject the binding protein of any one of claim 1 to 23 or 40 such that treatment is achieved.
Dependencies are inferred from the claim text.